Acute oxygen supplementation restores markers of hepatocyte energy status and hypoxia in cirrhotic rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 2, 2000, Pages 641-645

  Harvey, Peta J ^b   Gready, Jill E ^b   Yin, Zhanli ^b   Le Couteur, David G ^b   McLean, Allan J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; LACTIC ACID; OXYGEN; PERCHLORIC ACID; PYRUVIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD GAS ANALYSIS; CELL HYPOXIA; CONTROLLED STUDY; ENERGY METABOLISM; LIVER CELL; LIVER CIRRHOSIS; LIVER ISCHEMIA; LIVER METABOLISM; MALE; NONHUMAN; OXYGEN THERAPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RAT;

ANIMALS; ANOXIA; BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; CARBON TETRACHLORIDE POISONING; ENERGY METABOLISM; LACTIC ACID; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OXYGEN; PERCHLORIC ACID; PHOSPHORYLATION; PYRUVIC ACID; RATS; RATS, WISTAR;

EID: 0034011393     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. 31P nuclear magnetic resonance study in vivo of metabolic abnormalities in rats with acute liver failure. NMR Biomed 1:67-73.
2. Bobik A, Jennings G, Skews H, Esler M and McLean A (1981) Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypertension. Clin Pharmacol Ther 30:673-679.
3. Branch RA and Shand DG (1976) Propranolol disposition in chronic liver disease: A physiological approach. Clin Pharmacokinet 1:264-279.
4. 31P NMR spectroscopy. Magn Reson Med 20:100-112.
5. 31P magnetic resonance spectroscopy study. J Stud Alcohol 58:119-129.
6. Cuomo R, Dattilo M, Pumpo R, Capuano G, Boselli L and Budillon G (1994) Nicotinamide methylation in patients with cirrhosis. J Hepatol 20:138-142.
7. Cuomo R, Pumpo R, Sarnelli G, Capuano G and Budillon G (1995) Nicotinamide methylation and hepatic energy reserve: A study by liver perfusion in vivo. J Hepatol 23:465-470.
8. Czok R and Lamprecht W (1974) Pyruvate, phosphoenolpyruvate and D-glycerate-2-phosphate, in Methods of Enzymatic Analysis, 2nd ed. (Bergmeyer HU ed) pp 1446-1451, Verlag Chemie, Weinheim.
9. Desmoulin F, Canioni P, Crotte C, Gerolami A and Cozzone PJ (1987) Hepatic metabolism during acute alcohol administration: A phosphorus-31 nuclear magnetic resonance study on the perfused rat liver under normoxic and hypoxic conditions. Hepatology 7:315-353.
10. Froomes PRA, Morgan DJ, Smallwood RA and Angus PW (1999) Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology 116:915-920.
11. Gibson R, McLean AJ and Dudley FJ (1986) The hypotensive effect of nitroglycerine on portal venous pressure in patients with cirrhotic portal hypertension. J Gastroenterol Hepatol 1:201-206.
12. Gutmann I and Wahlefeld AW (1974) L-(+)-Lactate: Determination with lactate dehydrogenase and NAD, in Methods of Enzymatic Analysis, 2nd ed. (Bergmeyer HU ed) pp 1464-1468, Verlag Chemie, Weinheim.
13. 1H NMR spectroscopic studies of liver extracts of carbon tetrachloride-treated rats. NMR Biomed 12:395-401.
14. Harvey PJ, Le Couteur DG and McLean AJ (1999b) Hepatic oxygen supplementation as therapy in cirrhotic liver disease. Gastroenterology 117:1025-1026.
15. Heinzow BJ, Corbett H, Constantinides S, Bourne R and McLean AJ (1984) Interaction between oral hydralazine and propranolol pharmacokinetics. 1. Changes in absorption, presystemic clearance and splanchnic blood flow. J Pharmacol Exp Ther 229:509-515.
16. Heinzow BJ, Somogyi A and McLean AJ (1987) Influence of hydralazine on the pharmacokinetics of orally administered D-propranolol and lidocaine in conscious dogs. Arch Int Pharmacodyn Ther 286:5-14.
17. Hernandez-Munoz R, Diaz-Munoz M and Chagoya de Sanchez VC (1994) Possible role of cell redox state on collagen metabolism in carbon tetrachloride-induced cirrhosis as evidenced by adenosine administration to rats. Biochim Biophys Acta 1200:93-99.
18. Hernandez-Munoz R, Diaz-Munoz M, Suarez J and Chagoya de Sanchez VC (1990) Adenosine partially prevents cirrhosis induced by carbon tetrachloride in rats. Hepatology 12:242-248.
19. Hickey PL, Angus PW, McLean AJ and Morgan DJ (1995) Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats. Gastroenterology 108: 1504-1509.
20. Hickey PL, McLean AJ, Angus PW, Choo EF and Morgan DJ (1996) Increased sensitivity of propranolol clearance to reduced oxygen delivery in the isolated perfused cirrhotic rat liver. Gastroenterology 111:1039-1048.
21. 31P-n.m.r. spectroscopy and its implications for metabolic control. Biochem J 229:141-151.
22. Jalan R, Sargentoni J, Coutts GA, Bell JD, Rolles K, Burroughs AK and Taylor-Robinson SD (1996) Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. Gut 39:141-146.
23. Jones DP (1981) Hypoxia and drug metabolism. Biochem Pharmacol 30:1019-1023.
24. Jones DP. Aw TY and Shan X (1989) Drug metabolism and toxicity during hypoxia. Drug Metab Rev 20:247-260.
25. Kehrer JP, Jones DP, Lemasters JJ, Farber JL and Jaeschke H (1990) Mechanisms of hypoxic cell injury. Summary of the Symposium presented at the 1990 Annual Meeting of the Society of Toxicology. Toxicol Appl Pharmacol 106:165-178.
26. Le Couteur DG, Hickey HM, Harvey PJ, Gready JE and McLean AJ (1999) Hepatic artery flow and propranolol metabolism in the perfused cirrhotic rat liver. J Pharmacol Exp Ther 289:1553-1558.
27. Matsui Y, Okuda Y, Nakagawa M, Kwon A-H, Minoura T, Hiramatsu Y, Uetsuji S and Kamiyama Y (1994) Effect of hepatocyte volume on energy status in the cirrhotic rat liver. J Gastroenterol Hepatol 9:613-619.
28. McLean AJ and Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21:42-69.
29. McLean AJ, Skews H, Bobik A and Dudley FJ (1980) Interaction between oral propranolol and hydralazine mechanisms and therapeutic implications. Clin Pharmacol Ther 27:726-732.
30. Menon DK, Sargentoni J, Taylor-Robinson SD, Bell JD, Cox IJ, Bryant DJ, Coutts GA, Rolles K, Burroughs AK and Morgan MY (1995) Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: Biochemical basis of spectral appearances. Hepatology 21:417-427.
31. Meyerhoff DJ, Boska MD, Thomas AM and Weiner MW (1989) Alcoholic liver disease: Quantitative image-guided P-31 MR spectroscopy. Radiology 173:393-400.
32. Morgan DJ and McLean AJ (1995) Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clin Pharmacokinet 29:370-391.
33. Proctor E and Chatamra K (1982) High yield micronodular cirrhosis in the rat. Gastroenterology 83:1183-1190.
34. Reichen J, Arts B, Schafroth U, Zimmerman A, Zeltner TB and Zysset T (1987) Aminopyrine N-demethylation by rats with liver cirrhosis. Gastroenterology 93: 719-726.
35. 31P nuclear magnetic resonance study. Biochim Biophys Acta 1272:113-118.
36. Varin F and Huet P-M (1985) Hepatic microcirculation in the perfused cirrhotic rat liver. J Clin Invest 76:1904-1912.
37. 4-induced cirrhotic rat liver. Res Exp Med 189:153-161.
38. Weiner MW, Hetherington H, Hubesch B, Karczmar G, Massie B, Maudsley A, Meyerhoff DJ, Sappey-Marinier D, Schaefer S and Twieg DB (1989) Clinical magnetic resonance spectroscopy of brain, heart, liver, kidney, and cancer. A quantitative approach. NMR Biomed 2:290-297.